Peginterferon beta-1a
How it works: The first medicines: interferon beta and glatiramer acetate →
Plegridy
EU: Approved in the EU since 2014US: FDA approved 2014
- Molecule type
- Protein
- Mechanism (ChEMBL)
- Interferon alpha/beta receptor agonist
- Targets
- Interferon alpha/beta receptor
- Availability
- Authorised in all EU and EEA countries. Reimbursement is decided by each country.
Approvals
Safety communications
None recorded.
Most-reported side effects (FDA reports)
Reports to the FDA's adverse event system (FAERS) show what people and doctors reported while taking the medicine. They do not prove the medicine caused it, and they are not rates.
70 reports in total, 62 marked serious.
- Multiple sclerosis relapse22
- Dizziness10
- Nausea10
- Drug ineffective7
- Off label use7
- Anaemia6
- General physical health deterioration6
- Menorrhagia5
- Drug ineffective for unapproved indication4
- Therapy non-responder4
Trials
Key trials
Large trials with a reported result on their main goal.
- Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfid
Terminated · Phase 3 · Relapsing MS · Stopped: safety
- Characterize Flu-like Symptoms in Relapsing Multiple Sclerosis Patient
Completed · Phase 3 · Relapsing MS · Met its main goal
- Efficacy and Safety Study of Peginterferon Beta-1a in Participants Wit
Completed · Phase 3 · Relapsing MS · Met its main goal
Running now
- A Prospective Randomized Non-inferiority Trial Comparing Anti-CD20 Mai
Recruiting · Phase 3 · Relapsing and progressive · Still running
- Disease Modifying Therapies Withdrawal in Inactive Relapsing-remitting
Not yet recruiting · Phase 3 · Relapsing MS · Still running
- An Observational Study to Learn About the Interferon-beta Exposure of
Running, not recruiting · MS (type not specified) · Still running
- A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY
Running, not recruiting · Relapsing MS · Still running
- A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017
Running, not recruiting · Phase 3 · Relapsing MS · Still running
- Disease Modifying Therapies Withdrawal in Inactive Secondary Progressi
Running, not recruiting · Phase 3 · Progressive MS · Still running
Other trials (11)
Completed small trials, dose-finding studies and trials in other diseases.
- A Post-Authorization Safety Study of Interferon Beta Therapy in Partic
Completed · Relapsing MS · No results found
- Evaluating the Use of Prednisone to Decrease Pegylated Interferon Beta
Status unknown · Phase 4 · Relapsing and progressive · Paper found, not read
- Evaluate Safety/Tolerability in Portuguese Participants With RRMS Tran
Completed · Phase 4 · Relapsing MS · No results found
- EPID Multiple Sclerosis Pregnancy Study
Completed · MS (type not specified) · No results found
- Plegridy Satisfaction Study in Participants
Completed · Phase 4 · Relapsing MS · Missed its main goal
- Plegridy Observational Program
Completed · Relapsing MS · No results found
- Study to Evaluate the Pharmacokinetic Profiles of BIIB017 (Peginterfer
Completed · Phase 1 · MS (type not specified) · Paper found, not read
- Transition to Peginterferon Beta-1a (BIIB017) From Subcutaneous Interf
Withdrawn · Phase 4 · Relapsing MS · Stopped
- Biogen Multiple Sclerosis Pregnancy Exposure Registry
Completed · MS (type not specified) · Paper found, not read
- Long-Term Safety and Efficacy Study of Peginterferon Beta-1a
Completed · Phase 3 · Relapsing MS · Results posted, not judged
Trials where it is given as background therapy
- Brimonidine Tartrate for the Treatment of Injection Related Erythema
Withdrawn · Phase 4 · Relapsing MS · Stopped
For information only, not medical advice. Talk to your neurologist before changing treatment.
Hypotheses involving this medicine
Loading hypotheses…
Loading reviews and guidelines…
Lab studies
Lab studies in animals or cells. Results in animals often do not hold in people, and these studies never change the status of an idea.
Loading lab studies…